Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1

Drug Development Research

Volumn 53, Issue 4, 2001, Pages 260-267

  Parkes, David ^a   Jodka, Carolyn ^a   Smith, Pam ^a   Nayak, Sonali ^b   Rinehart, Liz ^b   Gingerich, Ron ^b   Chen, Kim ^a   Young, Andrew ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b Linco Research Inc   (United States)

Author keywords

Intravenous administration; Kinetics; Peptide; Subcutaneous administration

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNORADIOMETRIC ASSAY; MALE; NONHUMAN; PLASMA CLEARANCE; RAT;

EID: 0034752734     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.1195     Document Type: Article

References (6)

1. Deacon CF, Johnsen AH, Holst JJ. 1995. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957.
2. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. 1998. Dipeptidyl peptidase IV resistant analogues of glucagonlike peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278.
3. Egan JM, Clocquet AR, Elahi D. 1999. Insulinotropic effect of exendin-4 in humans. European Association for the Study of Diabetes, Brussels, September. Diabetologia 42:A41.
4. Eissele R, Bothe-Sandfort E, Goke B, Eng J, Arnold R, Koop H. 1994. Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci 55:629-634.
5. Eng J. 1992. Exendin peptides. Mt Sinai J Med 59:147-149.
6. Fehmann HC, Jiang J, Schweinfurth J, Wheeler MB, Boyd AE 3rd, Goke B. 1994. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 15:453-456.